Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever. Earlier this week, Novo Nordisk tore up a partnership with the telehealth storefront Hims & Hers Health,

Tufts University scientists are aiming to revolutionize the future of weight loss drugs by engineering a new compound that targets four gut hormones instead of the usual one to three. These next-gen tetra-functional peptides may overcome the limitations of current drugs like Ozempic and Mounjaro especially their nausea,